Cargando…

Serum Adalimumab Levels After Induction Are Associated With Long-Term Remission in Children With Inflammatory Bowel Disease

Introduction: Adalimumab is effective in inducing and maintaining remission in children with inflammatory bowel diseases (IBD). Therapeutic drug monitoring is an important strategy to maximize the response rates, but data on the association of serum adalimumab levels are lacking. This study aimed to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lucafò, Marianna, Curci, Debora, Bramuzzo, Matteo, Alvisi, Patrizia, Martelossi, Stefano, Silvestri, Tania, Guastalla, Veronica, Labriola, Flavio, Stocco, Gabriele, Decorti, Giuliana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pediatrics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8129012/ https://www.ncbi.nlm.nih.gov/pubmed/34017806 http://dx.doi.org/10.3389/fped.2021.646671

Ejemplares similares

Pharmacogenetic variants of infliximab response in young patients with inflammatory bowel disease
por: Curci, Debora, et al.
Publicado: (2021)

Atomic Force Microscopy Application for the Measurement of Infliximab Concentration in Healthy Donors and Pediatric Patients with Inflammatory Bowel Disease
por: Curci, Debora, et al.
Publicado: (2022)

Inflammatory Bowel Disease and Risk of Colorectal Cancer: An Overview From Pathophysiology to Pharmacological Prevention
por: Lucafò, Marianna, et al.
Publicado: (2021)

Gender May Influence the Immunosuppressive Actions of Prednisone in Young Patients With Inflammatory Bowel Disease
por: Lucafò, Marianna, et al.
Publicado: (2021)

A Validated HPLC–Diode Array Detection Method for Therapeutic Drug Monitoring of Thiopurines in Pediatric Patients: From Bench to Bedside
por: Franzin, Martina, et al.
Publicado: (2022)

Role of tristetraprolin phosphorylation in paediatric patients with inflammatory bowel disease
por: Di Silvestre, Alessia, et al.
Publicado: (2019)

Azathioprine Biotransformation in Young Patients with Inflammatory Bowel Disease: Contribution of Glutathione-S Transferase M1 and A1 Variants
por: Lucafò, Marianna, et al.
Publicado: (2019)

Long Non-Coding RNA GAS5 and Intestinal MMP2 and MMP9 Expression: A Translational Study in Pediatric Patients with IBD
por: Lucafò, Marianna, et al.
Publicado: (2019)

Microbiota and Drug Response in Inflammatory Bowel Disease
por: Franzin, Martina, et al.
Publicado: (2021)

Emerging Insights on the Interaction Between Anticancer and Immunosuppressant Drugs and Intestinal Microbiota in Pediatric Patients
por: Lucafò, Marianna, et al.
Publicado: (2019)

Patient-derived organoids for therapy personalization in inflammatory bowel diseases
por: Lucafò, Marianna, et al.
Publicado: (2022)

Pharmacogenomics of Antibiotics
por: Stocco, Gabriele, et al.
Publicado: (2020)

High-Throughput Sequencing of microRNAs in Glucocorticoid Sensitive Paediatric Inflammatory Bowel Disease Patients
por: De Iudicibus, Sara, et al.
Publicado: (2018)

Expression Pattern of Long Non-coding RNA Growth Arrest-specific 5 in the Remission Induction Therapy in Childhood Acute Lymphoblastic Leukemia
por: Gasic, Vladimir, et al.
Publicado: (2019)

Adalimumab in Pediatric Inflammatory Bowel Disease
por: Choi, So Yoon, et al.
Publicado: (2022)

PACSIN2 as a modulator of autophagy and mercaptopurine cytotoxicity: mechanisms in lymphoid and intestinal cells
por: Zudeh, Giulia, et al.
Publicado: (2023)

Pharmacogenetics of thiopurines
por: Franca, Raffaella, et al.
Publicado: (2019)

Induced pluripotent stem cells for therapy personalization in pediatric patients: Focus on drug-induced adverse events
por: Genova, Elena, et al.
Publicado: (2019)

miR-331-3p is involved in glucocorticoid resistance reversion by rapamycin through suppression of the MAPK signaling pathway
por: Lucafò, Marianna, et al.
Publicado: (2020)

Thalidomide for inflammatory bowel disease: Systematic review
por: Bramuzzo, Matteo, et al.
Publicado: (2016)

Subcutaneous tocilizumab in the management of non-infectious uveitis in children: a brief report
por: Burlo, Francesca, et al.
Publicado: (2023)

Adalimumab for induction of remission in patients with Crohn's disease: a systematic review and meta-analysis
por: Yin, Juntao, et al.
Publicado: (2022)

5-aminoimidazole-4-carboxamide ribonucleotide-transformylase and inosine-triphosphate-pyrophosphatase genes variants predict remission rate during methotrexate therapy in patients with juvenile idiopathic arthritis
por: Pastore, Serena, et al.
Publicado: (2014)

Prognostic Observational Analysis of BMI, Leptin, and Adiponectin in Children With Acute Lymphocytic Leukemia Undergoing Remission-Induction Chemotherapy
por: Sun, Jing, et al.
Publicado: (2022)

Higher Adalimumab Trough Levels Are Associated with Histologic Remission and Mucosal Healing in Inflammatory Bowel Disease
por: Wong, Rochelle, et al.
Publicado: (2023)

Remission and long-term remission of pediatric-onset systemic lupus erythematosus
por: Chen, Yi-Chieh, et al.
Publicado: (2023)

Adalimumab induction and maintenance therapy achieve clinical remission and response in Chinese patients with Crohn's disease
por: Wu, Kai-Chun, et al.
Publicado: (2016)

Efficacy of Switching to Adalimumab for Maintenance of Remission Following Induction Therapy with Tacrolimus in Patients with Ulcerative Colitis
por: Numa, Keijiro, et al.
Publicado: (2023)

Induced pluripotent stem cells as an innovative model to study drug induced pancreatitis
por: Genova, Elena, et al.
Publicado: (2021)

Central Nervous System Involvement in Childhood Acute Lymphoblastic Leukemia: An Analysis of Day-One Versus Day-Eight Lumbar Punctures in Remission Induction Therapy
por: Arshad, Uzma, et al.
Publicado: (2021)

Post-Induction High Adalimumab Drug Levels Predict Biological Remission at Week 24 in Patients With Crohn's Disease
por: Zittan, Eran, et al.
Publicado: (2021)

Biomarkers for gastrointestinal adverse events related to thiopurine therapy
por: Zudeh, Giulia, et al.
Publicado: (2021)

Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry Seven‐Year Interim Results
por: Brunner, Hermine I., et al.
Publicado: (2020)

Efficacy of adalimumab as second-line therapy in a pediatric cohort of Crohn’s disease patients who failed infliximab therapy: the Italian Society of Pediatric Gastroenterology, Hepatology, and Nutrition experience
por: Alvisi, Patrizia, et al.
Publicado: (2019)

Low dose Naltrexone for induction of remission in inflammatory bowel disease patients
por: Lie, Mitchell R. K. L., et al.
Publicado: (2018)

Case Report: An early-onset inflammatory colitis due to a variant in TNFAIP3 causing A20 haploinsufficiency
por: Zanatta, Laura, et al.
Publicado: (2022)

Peripheral Blood Lymphocyte Analysis in Oligo- and Polyarticular Juvenile Idiopathic Arthritis Patients Receiving Methotrexate or Adalimumab Therapy: A Cross-Sectional Study
por: Nagy, Arnold, et al.
Publicado: (2020)

Hypomethylation of NLRP3 gene promoter discriminates glucocorticoid‐resistant from glucocorticoid‐sensitive idiopathic nephrotic syndrome patients
por: Lucafò, Marianna, et al.
Publicado: (2021)

Comparative Effectiveness of Ustekinumab Versus Adalimumab in Induction of Clinical Response and Remission in Crohn’s Disease: Experience of a Real-World Cohort at a Tertiary Care Inflammatory Bowel Disease Referral Center
por: Ahmed, Zunirah, et al.
Publicado: (2019)

Demographics and clinical characteristics associated with sustained remission and continuation of sustained remission in patients with rheumatoid arthritis treated with adalimumab
por: Kimura, Noriko, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_m2o1ufp7aci6pvc8g9ln3n4btb